Victoza is a once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue which works by stimulating the beta cells to release insulin only when blood sugar levels are high.
The injection is indicated as an add-on to metformin or sulphonylurea (SU) in people with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin or SU.
According to the company, Victoza has been proven to lower blood sugar levels, reduce body weight, lower systolic blood pressure, and shows improvements in measurements of beta cell function, besides having a low risk of hypoglycaemia.
Victoza has been commercially launched in over 39 countries including the US, Japan, the Arabian Peninsula, and other countries in Europe, Asia and South America.